William Blair Analyst: DaVita Set to Gain from Medicare Advantage Reimbursement Increase

William Blair analyst Ben Andrew released comments Tuesday morning expressing confidence in DaVita Healthcare DVA, following the victory by health insurers to get the reimbursement for Medicare Advantage increased by 3.3 percent on Monday. The decision against a reduction in Medicare reimbursements was cited as a reduction in near-term headwinds, while also improving the company's position in the long-term. DaVita was highlighted as one of the "best positioned" companies to benefit from this ruling, and is maintained at an Outperform rating. Shares of DaVita Healthcare traded up 5.51 percent to $126.52.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorNewsLegalAnalyst RatingsMoversWilliam Blair
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!